Intercept Pharmaceuticals Profit Margin 2011-2021 | ICPT
Current and historical gross margin, operating margin and net profit margin for Intercept Pharmaceuticals (ICPT) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Intercept Pharmaceuticals net profit margin as of September 30, 2021 is -30.28%.
|Intercept Pharmaceuticals Annual Profit Margins
|Intercept Pharmaceuticals Quarterly Profit Margins
||Medical - Biomedical and Genetics
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.